December 2, 2016: Here are four stocks trading with relatively heavy volume among 42 equities making new 52-week lows in Monday’s session. On the NYSE, advancers led decliners by about 2.5 to 1 and on the Nasdaq advancers led decliners by more than 3 to 1.
FitBit Inc. (NYSE: FIT) lost about 2% Monday to post a new 52-week low of $7.98 after closing Friday at $8.14. The 52-week high is $34.68. Volume of around 11 million was about 20% above the daily average of around 9.8 million shares traded. A new report from IDC gave FitBit a 23% market share in the third quarter, but investors still don’t like the proposed acquisition of competitor Pebbles.
Protalix BioTherapeutics Inc. (NYSEMKT: PLX) dropped about 14% on Monday to post a new 52-week low of $0.27 against a 52-week high of $1.05 and a Friday close of $0.31. Volume of more than 10 million was about 30 times the daily average of around 300,000. The company had no specific news Monday.
AstraZeneca plc (NYSE: AZN) dropped about 0.8% on Monday to post a new 52-week low of $25.68 after closing at $25.89 on Friday. The stock’s 52-week high is $35.04. Volume was less than 10% higher than the daily average of around 6.2 million shares. The company reported continued progress related to its leukemia drug based on preliminary phase I and II clinical trials.
Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) dropped about 0.4% on Monday to post a new 52-week low of $36.40 after closing at $36.53 on Friday. The stock’s 52-week high is $66.55. Volume of about 5.3 million was about 15% below the daily average of 9 million. The company had no specific news Monday.
Find a Qualified Financial Advisor (Sponsor)
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
